335 related articles for article (PubMed ID: 9210041)
1. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
2. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
Vogel T; Kurth R; Norley S
J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
5. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
6. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
Kang CY; Hariharan K; Posner MR; Nara P
J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
[TBL] [Abstract][Full Text] [Related]
8. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of diagnostic efficiency of the recombinant protein modeling immunodominant epitope V3 of envelope gp120 for immunoenzyme detection for HIV-1 infection antibodies].
Riabinina SA; Baranova EN; Sharipova IN; Susekina MI; Puzyrev VF; Obriadina AP; Burkov AN; Ulanova TI
Mol Gen Mikrobiol Virusol; 2007; (3):33-6. PubMed ID: 17886471
[TBL] [Abstract][Full Text] [Related]
10. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
11. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
Trujillo JR; Rogers RA; Brain JD
Virology; 1998 Jun; 246(1):53-62. PubMed ID: 9656993
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
13. Improving on nature: focusing the immune response on the V3 loop.
Zolla-Pazner S
Hum Antibodies; 2005; 14(3-4):69-72. PubMed ID: 16720976
[TBL] [Abstract][Full Text] [Related]
14. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
Chamat S; Nara P; Berquist L; Whalley A; Morrow WJ; Köhler H; Kang CY
J Immunol; 1992 Jul; 149(2):649-54. PubMed ID: 1378074
[TBL] [Abstract][Full Text] [Related]
15. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
[TBL] [Abstract][Full Text] [Related]
16. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
Laisney IL; Benjamin H; Gefter M; Strosberg AD
Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
[TBL] [Abstract][Full Text] [Related]
17. CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination.
Deckert PM; Ballmaier M; Lang S; Deicher H; Schedel I
J Immunol; 1996 Jan; 156(2):826-33. PubMed ID: 8543839
[TBL] [Abstract][Full Text] [Related]
18. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
19. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
Devash Y; Rusche JR; Nara PL
Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
[TBL] [Abstract][Full Text] [Related]
20. Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.
Pantaleo G; Demarest JF; Vaccarezza M; Graziosi C; Bansal GP; Koenig S; Fauci AS
Eur J Immunol; 1995 Jan; 25(1):226-31. PubMed ID: 7843235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
